Literature DB >> 24843871

Role of Fc-mediated antibody function in protective immunity against HIV-1.

George K Lewis.   

Abstract

The importance of Fc-mediated effector function in protective immunity to HIV-1 (hereafter referred to simply as HIV) is becoming increasingly apparent. A large of number of studies in natural infection cohorts, spanning the last 26 years, have associated Fc-mediated effector function, particularly antibody-dependent cellular cytotoxicity, with a favourable clinical course. These studies strongly suggest a role for Fc-mediated effector function in the post-infection control of viraemia. More recently, studies in both humans and non-human primates (NHPs) also implicate Fc-mediated effector function in blocking HIV acquisition. Accordingly, this review will discuss the results supporting a role of Fc-mediated effector function in both blocking acquisition and post-infection control of viraemia. Parallel studies in NHPs and humans will be compared for common themes. Context for this discussion will be provided by summarizing the temporal emergence of key host and virological events over the course of an untreated HIV infection framing where, when and how Fc-mediated effector function might be protective. A hypothesis that Fc-mediated effector function protects primarily in the early stages of both acquisition and post-infection control of viraemia will be developed.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24843871      PMCID: PMC3992047          DOI: 10.1111/imm.12232

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  112 in total

1.  Comprehensive investigation of common antibody-dependent cell-mediated cytotoxicity antibody epitopes of HIV-1 CRF01_AE gp120.

Authors:  Silawun Ampol; Kovit Pattanapanyasat; Ruengpung Sutthent; Parichart Permpikul; Wannee Kantakamalakul
Journal:  AIDS Res Hum Retroviruses       Date:  2012-05-03       Impact factor: 2.205

2.  Sequential deregulation of NK cell subset distribution and function starting in acute HIV-1 infection.

Authors:  Galit Alter; Nickolas Teigen; Benjamin T Davis; Marylyn M Addo; Todd J Suscovich; Michael T Waring; Hendrik Streeck; Mary N Johnston; Kyle D Staller; M Tauheed Zaman; Xu G Yu; Mathias Lichterfeld; Nesli Basgoz; Eric S Rosenberg; Marcus Altfeld
Journal:  Blood       Date:  2005-07-07       Impact factor: 22.113

3.  Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells.

Authors:  Vincent Holl; Maryse Peressin; Thomas Decoville; Sylvie Schmidt; Susan Zolla-Pazner; Anne-Marie Aubertin; Christiane Moog
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

4.  Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family.

Authors:  Mattia Bonsignori; Justin Pollara; M Anthony Moody; Michael D Alpert; Xi Chen; Kwan-Ki Hwang; Peter B Gilbert; Ying Huang; Thaddeus C Gurley; Daniel M Kozink; Dawn J Marshall; John F Whitesides; Chun-Yen Tsao; Jaranit Kaewkungwal; Sorachai Nitayaphan; Punnee Pitisuttithum; Supachai Rerks-Ngarm; Jerome H Kim; Nelson L Michael; Georgia D Tomaras; David C Montefiori; George K Lewis; Anthony DeVico; David T Evans; Guido Ferrari; Hua-Xin Liao; Barton F Haynes
Journal:  J Virol       Date:  2012-08-15       Impact factor: 5.103

5.  Sustained antibody-dependent cell-mediated cytotoxicity (ADCC) in SIV-infected macaques correlates with delayed progression to AIDS.

Authors:  Nia D Banks; Nicole Kinsey; Janice Clements; James E K Hildreth
Journal:  AIDS Res Hum Retroviruses       Date:  2002-11-01       Impact factor: 2.205

6.  Lymphatic tissue fibrosis is associated with reduced numbers of naive CD4+ T cells in human immunodeficiency virus type 1 infection.

Authors:  Timothy W Schacker; Jason M Brenchley; Gregory J Beilman; Cavan Reilly; Stefan E Pambuccian; Jodie Taylor; David Skarda; Matthew Larson; Daniel C Douek; Ashley T Haase
Journal:  Clin Vaccine Immunol       Date:  2006-05

7.  Interactions between natural killer cells and antibody Fc result in enhanced antibody neutralization of human immunodeficiency virus type 1.

Authors:  Donald N Forthal; Gary Landucci; Tran B Phan; Juan Becerra
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

8.  An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum.

Authors:  Guido Ferrari; Justin Pollara; Daniel Kozink; Tiara Harms; Mark Drinker; Stephanie Freel; M Anthony Moody; S Munir Alam; Georgia D Tomaras; Christina Ochsenbauer; John C Kappes; George M Shaw; James A Hoxie; James E Robinson; Barton F Haynes
Journal:  J Virol       Date:  2011-05-04       Impact factor: 5.103

9.  Collagen deposition in HIV-1 infected lymphatic tissues and T cell homeostasis.

Authors:  Timothy W Schacker; Phuong L Nguyen; Gregory J Beilman; Steven Wolinsky; Matthew Larson; Cavan Reilly; Ashley T Haase
Journal:  J Clin Invest       Date:  2002-10       Impact factor: 14.808

10.  Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection.

Authors:  Jesus F Salazar-Gonzalez; Maria G Salazar; Brandon F Keele; Gerald H Learn; Elena E Giorgi; Hui Li; Julie M Decker; Shuyi Wang; Joshua Baalwa; Matthias H Kraus; Nicholas F Parrish; Katharina S Shaw; M Brad Guffey; Katharine J Bar; Katie L Davis; Christina Ochsenbauer-Jambor; John C Kappes; Michael S Saag; Myron S Cohen; Joseph Mulenga; Cynthia A Derdeyn; Susan Allen; Eric Hunter; Martin Markowitz; Peter Hraber; Alan S Perelson; Tanmoy Bhattacharya; Barton F Haynes; Bette T Korber; Beatrice H Hahn; George M Shaw
Journal:  J Exp Med       Date:  2009-06-01       Impact factor: 14.307

View more
  48 in total

Review 1.  Beyond Viral Neutralization.

Authors:  George K Lewis; Marzena Pazgier; David T Evans; Guido Ferrari; Stylianos Bournazos; Matthew S Parsons; Nicole F Bernard; Andrés Finzi
Journal:  AIDS Res Hum Retroviruses       Date:  2017-02-16       Impact factor: 2.205

2.  Fc Receptor-Mediated Activities of Env-Specific Human Monoclonal Antibodies Generated from Volunteers Receiving the DNA Prime-Protein Boost HIV Vaccine DP6-001.

Authors:  Matthew R Costa; Justin Pollara; Regina Whitney Edwards; Michael S Seaman; Miroslaw K Gorny; David C Montefiori; Hua-Xin Liao; Guido Ferrari; Shan Lu; Shixia Wang
Journal:  J Virol       Date:  2016-10-28       Impact factor: 5.103

3.  Capacity for infectious HIV-1 virion capture differs by envelope antibody specificity.

Authors:  Pinghuang Liu; Latonya D Williams; Xiaoying Shen; Mattia Bonsignori; Nathan A Vandergrift; R Glenn Overman; M Anthony Moody; Hua-Xin Liao; Daniel J Stieh; Kerrie L McCotter; Audrey L French; Thomas J Hope; Robin Shattock; Barton F Haynes; Georgia D Tomaras
Journal:  J Virol       Date:  2014-02-19       Impact factor: 5.103

4.  Improving the CH1-CK heterodimerization and pharmacokinetics of 4Dm2m, a novel potent CD4-antibody fusion protein against HIV-1.

Authors:  Weizao Chen; Ariola Bardhi; Yang Feng; Yanping Wang; Qianqian Qi; Wei Li; Zhongyu Zhu; Marzena A Dyba; Tianlei Ying; Shibo Jiang; Harris Goldstein; Dimiter S Dimitrov
Journal:  MAbs       Date:  2016-03-10       Impact factor: 5.857

5.  Passively acquired antibody-dependent cellular cytotoxicity (ADCC) activity in HIV-infected infants is associated with reduced mortality.

Authors:  Caitlin Milligan; Barbra A Richardson; Grace John-Stewart; Ruth Nduati; Julie Overbaugh
Journal:  Cell Host Microbe       Date:  2015-04-08       Impact factor: 21.023

Review 6.  Survivors Remorse: antibody-mediated protection against HIV-1.

Authors:  George K Lewis; Marzena Pazgier; Anthony L DeVico
Journal:  Immunol Rev       Date:  2017-01       Impact factor: 12.988

7.  Multimeric Epitope-Scaffold HIV Vaccines Target V1V2 and Differentially Tune Polyfunctional Antibody Responses.

Authors:  Ann J Hessell; Rebecca Powell; Xunqing Jiang; Christina Luo; Svenja Weiss; Vincent Dussupt; Vincenza Itri; Alisa Fox; Mariya B Shapiro; Shilpi Pandey; Tracy Cheever; Deborah H Fuller; Byung Park; Shelly J Krebs; Maxim Totrov; Nancy L Haigwood; Xiang-Peng Kong; Susan Zolla-Pazner
Journal:  Cell Rep       Date:  2019-07-23       Impact factor: 9.423

Review 8.  Epitope target structures of Fc-mediated effector function during HIV-1 acquisition.

Authors:  George K Lewis; Yongjun Guan; Roberta Kamin-Lewis; Mohammad Sajadi; Marzena Pazgier; Anthony L Devico
Journal:  Curr Opin HIV AIDS       Date:  2014-05       Impact factor: 4.283

9.  Quantification of the epitope diversity of HIV-1-specific binding antibodies by peptide microarrays for global HIV-1 vaccine development.

Authors:  Kathryn E Stephenson; George H Neubauer; Ulf Reimer; Nikolaus Pawlowski; Tobias Knaute; Johannes Zerweck; Bette T Korber; Dan H Barouch
Journal:  J Immunol Methods       Date:  2014-11-15       Impact factor: 2.303

10.  Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo.

Authors:  Ching-Lan Lu; Dariusz K Murakowski; Stylianos Bournazos; Till Schoofs; Debolina Sarkar; Ariel Halper-Stromberg; Joshua A Horwitz; Lilian Nogueira; Jovana Golijanin; Anna Gazumyan; Jeffrey V Ravetch; Marina Caskey; Arup K Chakraborty; Michel C Nussenzweig
Journal:  Science       Date:  2016-05-05       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.